← Eichor
Condition: Hemolytic Disease Of Newborn Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Hemolytic Disease Of Newborn

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
EARLY_Phase 1 · 1 location(s) · First Affiliated Hospital of Guangxi Medical University · NCT05762510Oral Ketamine for Treatment of Vaso-Occlusive Pain
Phase 3 · 1 location(s) · Boston Children's Hospital · NCT05378555A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates
Phase N/A · 1 location(s) · National Human Genome Research Institute (NHGRI) · NCT06092346PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD
Phase 1 · 1 location(s) · Enrico Novelli · NCT04925492ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
Phase 1/Phase 2 · 1 location(s) · Children's Hospital of Philadelphia · NCT06364774A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
Phase N/A · 6 location(s) · Genetix Biotherapeutics Inc. · NCT06271512Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
Phase 1 · 1 location(s) · Daniel Bauer · NCT06647979Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia
Phase 1/Phase 2 · 1 location(s) · The Hospital for Sick Children · NCT05426252Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
EARLY_Phase 1 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT06313398Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX)
Phase N/A · 1 location(s) · St. Jude Children's Research Hospital · NCT05810181Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy
NA · 1 location(s) · Washington University School of Medicine · NCT06689800Metabolic and Hemodynamic Reserve in Pediatric SCA
NA · 1 location(s) · Washington University School of Medicine · NCT04406818Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carryi
Phase 1/Phase 2 · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT07432867Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT03279094A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult
Phase 3 · 32 location(s) · Novartis Pharmaceuticals · NCT06439082The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Phase 3 · 53 location(s) · Sanofi · NCT06975865Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children
Phase 2 · 6 location(s) · Theravia · NCT06578507A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Phase 3 · 174 location(s) · Novo Nordisk A/S · NCT06612268Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
Phase 1 · 1 location(s) · Abdullah Kutlar · NCT01245179Adherence of Beta Thalssemia Patients to Oral Chelation Therapy
NA · 1 location(s) · Sohag University · NCT06568926National Longitudinal Cohort of Hematological Diseases
Phase N/A · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT04645199Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
Phase 2 · 1 location(s) · University of Illinois at Chicago · NCT03121001Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease
EARLY_Phase 1 · 1 location(s) · The 923rd Hospital of Joint Logistics Support Force of Peopl · NCT06107400A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Phase 3 · 105 location(s) · Novo Nordisk A/S · NCT06609226RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)
Phase N/A · 1 location(s) · Hospital Universitari Vall d'Hebron Research Institute · NCT06213402CS-206 in Patients With Sickle Cell Disease
EARLY_Phase 1 · 1 location(s) · CorrectSequence Therapeutics Co., Ltd · NCT06565026Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal Hyperbilirubinemia
Phase 4 · 1 location(s) · Amira Adel Fouly · NCT06517862A Phase 2/3 Study in Adult and Adolescent Participants With SCD
Phase 2/Phase 3 · 49 location(s) · Pfizer · NCT05431088Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Diseas
Phase 3 · 7 location(s) · Sanofi · NCT07247188A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an
Phase 2 · 6 location(s) · Memorial Sloan Kettering Cancer Center · NCT05736419
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.